B-cell lymphoma-associated hemophagocytic lymphohistiocytosis: A case report

Oncol Lett. 2022 Jun 7;24(2):246. doi: 10.3892/ol.2022.13365. eCollection 2022 Aug.

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition characterized by an exaggerated but dysregulated immune response resulting in hyperinflammation, with a potential for progression to multiple organ dysfunction and failure. Infectious diseases, inflammatory disorders, malignancies and immunodeficiency syndromes are known triggers of HLH in adults. The present study reported the case of a middle-aged man with HLH triggered by B-cell lymphoma who was successfully treated with dexamethasone; etoposide, prednisone, vincristine, cyclophosphamide, hydroxy-doxorubicin and rituximab chemotherapy; and multiple intrathecal methotrexate with a good outcome.

Keywords: B-cell lymphoma; chemotherapy; hemophagocytic histiocytosis; hyperinflammation.

Publication types

  • Case Reports

Grants and funding

Funding: No funding was received.